Carvedilol is an antihypertensive drug used for management of hypertension. It has short half-life and less oral bioavailability due to first pass metabolism. Hence, it required frequent dosing. The present study was aimed to formulate reservoir-type patch of carvedilol and establishment of correlation between ex-vivo and in-vivo drug release. Transdermal patches of carvedilol were prepared to sustain the drug release and to improve the bioavailability of drug and for patient compliance. Reservoir-type transdermal formulations were prepared by varying the amount of eudragit RL 100 and eudragit RS 100 employing solvent casting method. A 32 full factorial design was applied to check the effect of eudragit-RL 100 (X1) and eudragit RS 100 (X2) on the responses i.e. tensile strength, percentage drug released in 20 hr (Q20) and diffusion coefficient (n) as dependent variables. In-vitro release data were fitted to various models to ascertain the kinetic of drug release batch F1 was considered optimised batch and it was subjected to ex-vivo study and in-vivo study. The bioavailability studies in wistar rats indicated that the carvedilol loaded transdermal patches provided steady-state plasma concentration and improved bioavailability in comparison to oral administration. Area under the curve from time 0 to t (AUC0–t) values of in-vivo data to the ex-vivo cumulative amounts delivered were compared and level A correlation was observed.
Loading....